Several factors affect bone marrow volume reduction

	Tweet

Several factors affect bone marrow volume reduction and red blood cell depletion prior to transplantation.

According to recent research published in the journal Bone Marrow Transplantation, “The COBE Spectra is used to volume/red blood cell (RBC) deplete BM before transplantation or cryopreservation.

“We have audited our results to identify the effect of transit time, refrigerated storage, age and cellular composition on mononuclear cells (MNC) and CD34+ cell recoveries, volume/RBC depletion and neutrophil engraftment.”

"In total, 88 consecutive collections from autologous (n=25) and allogeneic (n=63) donors were included. The mean collection volume was 1250±398 ml with RBC content of 341±113 mL. The MNC and CD34+ cell recoveries were 83.3±18.5 and 88.1±18.9%, respectively, volume depletion was 88.2±4.4% and RBC depletion 98.3±1.8%.

“Neutrophil engraftment was achieved in 20.176.4 days. Factors affecting MNC and CD34+ cell recoveries were transit time (p=0.0060), overall age (p<0.0210) and MNC/CD34+ cell concentrations (p<0.0313). The presence of crenated RBC also reduced CD34+ cell recovery (p=0.0028),” reported scientists.

M.G. Guttridge and colleagues at the NHS Blood & Transplant in Bristol continued, “Refrigerated storage did not adversely affect cell recovery (p>0.8161) or neutrophil engraftment (p=0.8959).”

“This study demonstrates that time in transit, overall age, MNC and CD34+ cell concentrations and RBC condition were important factors affecting processing. RBCs show artefacts soon after collection at ambient temperatures and these may interfere with the separation and collection of MNC/CD34+ cells.

“Refrigeration at 4-6 degrees C during transit and storage may reduce formation of RBC artefacts and maximize MNC and CD34+ cell recoveries,” investigators concluded.

Guttridge and colleagues published their study in Bone Marrow Transplantation (Factors affecting volume reduction and red blood cell depletion of bone marrow on the COBE spectra cell separator before haematopoietic stem cell transplantation. Bone Marrow Transplant, 2006;38(3):175-181).

For additional information, contact M.G. Guttridge, NHS Blood & Transplant, National Blood Service Bristol, Stem Cells & Immunotherapies Laboratories, Bristol BS10 5ND, Avon, England.

RELATED STORIES:
Bone loss seen in kids after stem cell therapy   Researchers Explore Issues Related to Multiple Myeloma Treatment   Injured Marines at risk for abnormal bone growth   Immune-Based Drug Approved in Europe for Pediatric Cancer Patients   Children with bone cancer in their arms or legs survival rate improved   Going out on a limb   Whites at greatest risk for rare bone cancer   Backyard Garden May Yield Leukemia Treatment   Children with bone cancer at risk for second cancer   Drug Used for Advanced Cancer Could Cause Exposed Bone in Jaw   Towards more effective treatment for multiple myeloma   Freezing Bone Cancer Tumors Reduces Pain   New study shows positive role physical therapists play in lymphedema diagnois and treatment   Creating New Life Forms That May Help Eradicate Cancer Affecting Women   Children with cancer risk fragile bones   Oral Drug Sets New Survival Standard for Bone Marrow Cancer   Leukemia risk from chlorination seen mixed   New Hope for Deadly Childhood Bone Cancer   U of M researchers look to dogs to better understand intricacies of bone cancer   A New Way to Build Bone   Pesticides raise child risk of leukaemia   Radical Surgery Removes Half of Pelvis, Saves Leg

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]